Department of Tissue Regeneration, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, the Netherlands.
Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
J Tissue Eng Regen Med. 2018 Jan;12(1):e150-e158. doi: 10.1002/term.2453. Epub 2017 Aug 21.
Tissue engineered constructs (TECs) based on spheroids of bone marrow mesenchymal stromal cells (BM-MSCs) combined with calcium phosphate microparticles and enveloped in a platelet-rich plasma hydrogel showed that aggregation of MSCs improves their ectopic bone formation potential. The stromal vascular fraction (SVF) and adipose-derived MSCs (ASCs) have been recognized as an interesting MSC source for bone tissue engineering, but their ectopic bone formation is limited. We investigated whether aggregation of ASCs could similarly improve ectopic bone formation by ASCs and SVF cells. The formation of aggregates with BM-MSCs, ASCs and SVF cells was carried out and gene expression was analysed for osteogenic, chondrogenic and vasculogenic genes in vitro. Ectopic bone formation was evaluated after implantation of TECs in immunodeficient mice with six conditions: TECs with ASCs, TECs with BM-MSC, TECs with SVF cells (with and without rhBMP2), no cells and no cells with rhBMP2. BM-MSCs showed consistent compact spheroid formation, ASCs to a lesser extent and SVF showed poor spheroid formation. Aggregation of ASCs induced a significant upregulation of the expression of osteogenic markers like alkaline phosphatase and collagen type I, as compared with un-aggregated ASCs. In vivo, ASC and SVF cells both generated ectopic bone in the absence of added morphogenetic proteins. The highest incidence of bone formation was seen with BM-MSCs (7/9) followed by SVF + rhBMP2 (4/9) and no cells + rhBMP2 (2/9). Aggregation can improve ectopic bone tissue formation by adipose-derived cells, but is less efficient than rhBMP2. A combination of both factors should now be tested to investigate an additive effect.
基于骨髓间充质基质细胞(BM-MSCs)球体与磷酸钙微粒结合并包裹在富含血小板的血浆水凝胶中的组织工程构建体(TEC)表明,MSC 的聚集可提高其异位成骨潜力。基质血管成分(SVF)和脂肪来源的间充质干细胞(ASCs)已被认为是骨组织工程中一种有趣的 MSC 来源,但它们的异位成骨能力有限。我们研究了 ASCs 的聚集是否可以类似地改善 ASCs 和 SVF 细胞的异位成骨。进行了 BM-MSCs、ASCs 和 SVF 细胞的聚集,并在体外分析了成骨、软骨和成血管基因的基因表达。在免疫缺陷小鼠中植入 TECs 后,评估了异位骨形成,共设 6 种条件:含 ASCs 的 TECs、含 BM-MSC 的 TECs、含 SVF 细胞(含或不含 rhBMP2)的 TECs、无细胞的 TECs和无细胞但含 rhBMP2 的 TECs。BM-MSCs 表现出一致的致密球体形成,ASCs 则程度较小,SVF 则表现出较差的球体形成。与未聚集的 ASCs 相比,ASCs 的聚集诱导了骨形成标志物如碱性磷酸酶和 I 型胶原的表达显著上调。在体内,在没有添加形态发生蛋白的情况下,ASCs 和 SVF 细胞均能产生异位骨。骨形成发生率最高的是 BM-MSCs(7/9),其次是 SVF+rhBMP2(4/9)和无细胞+rhBMP2(2/9)。聚集可以改善脂肪来源细胞的异位骨组织形成,但效率低于 rhBMP2。现在应测试这两种因素的组合,以研究其相加效应。